{"name":"MorphoSys AG","slug":"morphosys-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":100000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Xmab5574","genericName":"tafasitamab","slug":"tafasitamab","revenue":100000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2020-01-01","label":"Xmab5574 first approved","drug":"Xmab5574","drugSlug":"tafasitamab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-11-01","label":"MONJUVI Phase 3 readout (Diffuse Large B-cell Lymphoma)","drug":"MONJUVI","drugSlug":"tafasitamab-cxix","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":100000000,"percentOfTotal":100,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Xmab5574","genericName":"tafasitamab","slug":"tafasitamab","indication":"Diffuse large B-cell lymphoma refractory","status":"discontinued","revenue":100000000},{"name":"MONJUVI","genericName":"TAFASITAMAB-CXIX","slug":"tafasitamab-cxix","indication":"Diffuse large B-cell lymphoma refractory","status":"marketed"}]}],"pipeline":[{"name":"Xmab5574","genericName":"tafasitamab","slug":"tafasitamab","phase":"discontinued","mechanism":"Tafasitamab works by binding to the CD19 antigen on B-lymphocytes, triggering an immune response against cancer cells.","indications":["Diffuse large B-cell lymphoma refractory","Malignant lymphoma, large B-cell, diffuse"],"catalyst":""},{"name":"MONJUVI","genericName":"TAFASITAMAB-CXIX","slug":"tafasitamab-cxix","phase":"marketed","mechanism":"B-lymphocyte antigen CD19","indications":["Diffuse large B-cell lymphoma refractory","Malignant lymphoma, large B-cell, diffuse"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQeWxTYkNRaFpGOUF4am91ZUhYNDUxRFNtb0NLbl96YTRMU3JCazlHbS13ZW1zbVMwVExqZV84Mm1teURFaVJvYXRaR0dIVzlSNkFIQmFrWkRtZ2lQMlpDZ3JnVFY5THBDc2tObFd4d25qeW5vSlJHZ0lkZzM4dnFSMVRTa2FOQ0tMUDdlcTRjVTBzQVA1S2NrUUhR?oc=5","date":"2025-08-11","type":"deal","source":"BioPharma Dive","summary":"Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease - BioPharma Dive","headline":"Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNUHE5MUpFcXlvZGNheTI1Y3ZJdk5aRU1SYVNTRl9uM2JCNlpKSTdqbnBxZEZGV0lKVHhyQTllODRpdVVwNUhjbE41RXZ1cHF4X1Baa3dWUXNQOWVjZ29xYkdzc1dpY0tsd3dlU3lfMEliU1RSTGpqRjd6ZW1OSTNxVWstd3B2bkJyaEhIVFlPbVo0QUU3dWlZbzk5eFMzNVFiOWhPa3Y1RHVGdEltOXFLdjN3SQ?oc=5","date":"2024-12-19","type":"deal","source":"Fierce Pharma","summary":"Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation - Fierce Pharma","headline":"Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOelhSSGlHZnBKWmNYZDdQTjNLcEdiWXdHVjNyWFVaN3huQUp0cENZSGpNcjJZaDI4TzhFV3BENVVBWVRfcExaLUo0N1F0RDJqbERjU0hsTW5zVW5kUTZ1TzVqMHFYT3RaZHF1Skh2VldyUkJvWGxxand1cE5GMGJiV3hGelhpemJxMnRiLXkwS3dqMmZMYzZ5Wjh5ZzNkOGh2ZmFaRTV1QkRURGs?oc=5","date":"2024-10-29","type":"pipeline","source":"Fierce Biotech","summary":"Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years - Fierce Biotech","headline":"Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxORHJua3dJSkx1RDRlWnZTbXdMMktHM3hqMTFJbm5vbWJZenZDYzhpWmlpbnFQeFZjM3Z4TWQzTzNkbmtMbmNwQ01XZDNOakRIdEpaVVhabHl3OUhWcGd6SGs3UGVhalIzMHNJVnVfbHF2SjFxVEJHeFRjS08yeUdsa3ZjQU4xLXQtdW8xYzRXbWgzUUFWVDdDa21vYUpNSkdmRXdDOEpuTkkwU1YyUExVdkYyUEw0MnZYYTdDanNHZF9WaG9jcDNBVmRabWdnenFuUFRRbHBVb0tubWMtV05OOUZXQVhwaFczeDZkMTRRX3VBWU14ZHlZRUpRSVk4U0FOaEFEV085QWI4SE1JbU9sOHZB?oc=5","date":"2024-06-20","type":"deal","source":"businesswire.com","summary":"MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders - businesswire.com","headline":"MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1MdXFrVHE4Z3VpckNqQW9yT1paVFdYQ090dUQ4cm1aZTVvbVpkUl9ubUo4QklKTDdfQlpLLVJyaVMxYkJ6R1FpNnhWbVRmS3FJaEhWTjhHWHB1SjQwOS1mcnRwODVXZUNid3ZBcQ?oc=5","date":"2024-02-07","type":"deal","source":"Pharmaceutical Executive","summary":"Novartis To Acquire MorphoSys AG - Pharmaceutical Executive","headline":"Novartis To Acquire MorphoSys AG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQZG00R19zSVFJR0tfenpadF9CcDB4bU95bEs2VDJDMjVuYkFyckZlLXNkS1FzZ1J6XzZzcUFleWpDbkxIU2ZmWW9adWNFbGtDRkxfaUt1MTFuM0dVblBRa3NJcm51SENmZXVQS0lyNFpGRmsyNGswcElXb3k1c2JLOEJVUmtOa1Q5cXhzWk0tbw?oc=5","date":"2024-02-06","type":"deal","source":"Contract Pharma","summary":"Novartis to Acquire MorphoSys AG for €2.7B - Contract Pharma","headline":"Novartis to Acquire MorphoSys AG for €2.7B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQQ1pGMFNBNy1qQWpTaXhHVkMxOG9zMFNLZUNEY1pTdlBIeXN0cXZpbC1sSVhFNGx2YzhMR0Z3SU1QTVJ3QWJTT2NxbW9VRGp1WXJxVURIM1BCNHJaQkNKczRUOHlvSWVUTUZyN3dxd3luY2otTXdXNk8wcFJMM0k3RkpQM3NGTC00U0ZmUzg2dkVFVnFNVVZxQzBSQ2QybnlhbEpmOGZPOVEzZw?oc=5","date":"2024-02-06","type":"deal","source":"Reuters","summary":"Novartis to acquire cancer-focused MorphoSys for $2.9 billion - Reuters","headline":"Novartis to acquire cancer-focused MorphoSys for $2.9 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNX1ctdm1pSkdkcmh0a2Z2R0hHYmRwVHUzRWY3eUc4TTRqdmFIZFVBSEN5aEtIMUljYWpjbzJhTnVhS2xfSnBVOGpiMFBxU29tZXFWcVIwMXROUDd3b1dRVERUZmVpMGdzQ25hN1lCdDFXQTBvTGc4VE0tN2FoM0RDNkJmVU1JbXpGTFBZREJMZXRLQWdCYkZUQ05nVjVYUEJO?oc=5","date":"2024-02-06","type":"pipeline","source":"BioWorld News","summary":"Novartis paying €2.7B for longtime antibody player Morphosys - BioWorld News","headline":"Novartis paying €2.7B for longtime antibody player Morphosys","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5CclR0Zk5LZVNWQmhCdUgtOXhnOHhpU0cyTDJPZzRpaHZFSlNMRlFadVVoME5xRjRzUVpsY1dHQmRzX3Q2Skw3Qk9Pd3V5a0kyZGJKZVZDU0E3YlV3VDdvazdfTk9qcWptY1haejRjS2k1NG9OenZWTzdMeThXb0U?oc=5","date":"2024-02-06","type":"pipeline","source":"pharmaphorum","summary":"More pharma M&A as Novartis snaps up MorphoSys for $2.9bn - pharmaphorum","headline":"More pharma M&A as Novartis snaps up MorphoSys for $2.9bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQdk5lYjF1LUJDN2VSMkZZb2NvdGc0QkU1eVFYanNMalhHbmVPQnUwaUpkTjhDN1loZktQQUUzNWpETGEwSUNZdzVfZXQzTGJrOUdBWnppN3IxSWtXRUlTYmViY3B2MjVzM0N3M2xxdnZGWDl1Tlh0NnU2aWVXMTdXQ3ZwcmNLSHZ0NGE4dEJhUUs4ZlNwdEtvS1M3WlFMWUkwcG9URC13c2lrT3NoSm95WXdaT1ZQVWN6LW1oVG9JSlhoTTNsS3lyel8xYVBHZFVzMHZBUUw0eUNEVjFEMjQ5WXVPR0k3blRY?oc=5","date":"2024-02-05","type":"deal","source":"Novartis","summary":"Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash - Novartis","headline":"Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNdERtcmV1QlJmVERGOUo2VFJXcHJUT29Hd2V4UmxjQ2xJdWZteHNDV0M2VW1Lc3lUMmRxOXBoUjJwZGNma2g3Z2tFLURFQ29nX2dHcENzankwSklIT2JFbk5CWXRHYnpWLXRkcHkwLVNtRFY4UEsxcTdYOW9DVlB0eGdEM1R4OFYySFhCYVJNaDhYQktydXRBdHhiTUF6Q3NKQ1BidG4wLTFPMTFtMU1WYzRBY25Jdw?oc=5","date":"2024-02-05","type":"deal","source":"Bloomberg.com","summary":"Novartis Buys MorphoSys for €2.7 Billion to Get Cancer Drugs - Bloomberg.com","headline":"Novartis Buys MorphoSys for €2.7 Billion to Get Cancer Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPa1dRMFNtcFVIYTJCdlR2bkJsMFVzaW5DMmxMTXRmVFBaRlFidG0ySmE4anZ4d1h4aDVOOWU2UlJEWEJjMTZmRnZMOUtWY0lldURMUEk2WWFuVW9sbXc3QUE1RlhoM1dhcG9IN2NSMTNvR29fT3lGUGlBSk9abjlmWk5VRDkza3NpWDFwOHJ0NV9vRHpwclJFRmdNR2d5aTJva0lhR04xRmgzQ09pNDRNVXNFbw?oc=5","date":"2021-06-02","type":"deal","source":"BioSpace","summary":"MorphoSys Pharma's Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma - BioSpace","headline":"MorphoSys Pharma's Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"discontinued":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}